Leerink Partners Issues Outperform Rating for Arcturus Therapeutics Holdings Inc (ARCT) Stock
Leerink Partners has recently initiated Arcturus Therapeutics Holdings Inc (ARCT) stock to Outperform rating, as announced on August 12, 2024, according to Finviz. Earlier, on December 13, 2023, Canaccord Genuity had initiated the stock to Buy, setting a price target of $90. William Blair also initiated Outperform rating with a price target of $71. Additionally, […]
Are Arcturus Therapeutics Holdings Inc’s (ARCT) stock prices rising too high?
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
What Are the Chances of Arcturus Therapeutics Holdings Inc (ARCT) Stock Making a Comeback?
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
Invest in Arcturus Therapeutics Holdings Inc (ARCT) Stock with the prospect of future returns
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
There Is Nothing Like Arcturus Therapeutics Holdings Inc (ARCT) Stock
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
How Arcturus Therapeutics Holdings Inc (ARCT) Stock converts water flow into cash flow
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
A Real Picture of Arcturus Therapeutics Holdings Inc (ARCT) Stock: The Fundamentals
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
Does Arcturus Therapeutics Holdings Inc (ARCT) Stock Really Excited You?
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
The Technical Story of Arcturus Therapeutics Holdings Inc (ARCT) Stock
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
A positive surprise is on the way: Arcturus Therapeutics Holdings Inc (ARCT) Stock
Canaccord Genuity raised the price target for the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) stock to “a Buy”. The rating was released on December 13, 2023, according to finviz. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $51. The stock was resumed by Wells […]
